

< . >

: . (2003-17 , 2003.4.14.) 2 1 2 [2]

	1	2	3	4							5		6		7	8
			가	가							가		가			
1.		x	x	x	x	x	x	x	x	x	x	X	X	x		
2.		x	x	X	X	x	x	x	x	x	X	X	X	x		
3.																

* : 1 8 5 1 1 8 .

1.

3.

1) 가

5.

가.

- 1) Penciclovir phosphate formation and stability in varicella-zoster virus infected MRC-5 cells
- 2) Prolonged inhibition of varicella-zoster DNA synthesis by penciclovir
- 3) Inhibition of clinical isolates of varicella-zoster virus by penciclovir and acyclovir in Hs68 cells

6.

가. &

- 1) A two part open randomized, crossover study to compare the bioavailability of commercial and clinical trial formulations of famciclovir following the oral administration of doses of 250mg and 750mg
- 2) A randomized, single-blind, crossover study to asses the degree of proportionality between pharmacokinetic parameter relating to BRL39123

and single oral doses of BRL42810 in the dose range 125-750mg

- 3) An open randomized, crossover study to assess the bioequivalence of a reduced weight tablet and the market image formulation of famciclovir following the oral administration of 500mg to healthy volunteers

- 1) A double-blind, double-dummy, randomized, acyclovir-controlled, parallel group study to compare the safety and efficacy of famciclovir dosed at 250mg tid, 500mg bid and 750mg od with aciclovir in the treatment of patients with uncomplicated Herpes Zoster

- 1) Dissolution data

7.

가. 가

8.